BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CPC Scientific - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://test.cpcscientific.com
X-WR-CALDESC:Events for CPC Scientific
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20230919T100000
DTEND;TZID=UTC:20230919T103000
DTSTAMP:20260521T041325
CREATED:20230909T010754Z
LAST-MODIFIED:20230909T030303Z
UID:10000032-1695117600-1695119400@test.cpcscientific.com
SUMMARY:PRRT Case Study Presentation at the 2023 Boulder Peptide Symposium
DESCRIPTION:Join John Phipps for his presentation on the manufacturing process of DOTAGA-Labeled Urea-Based Peptide PSMA Inhibitor. \nPeptide receptor radionuclide therapy (PRRT) is a targeted therapeutic strategy that uses peptides to deliver cytotoxic radiation levels to specific receptors overexpressed in cancer cells. Peptides are advantageous as therapeutic vectors in PRRT due to their small size\, favorable pharmacokinetics\, high binding affinity\, low immunogenicity and toxicity\, and minimal off-target binding. Tumor-targeting peptides conjugated to a radionuclide chelate constitute a new and powerful class of cancer medicines. Somatostatin\, cytokine (e.g.\, IL-13Ra2)\, and integrins receptors\, as well as vascular endothelial growth factor (VEGF)\, programmed death-ligand 1 (PD-L1)\, and prostate-specific membrane antigen (PSMA)\, have emerged as key targets for peptide radionuclide therapeutics. PSMA is an attractive target for prostate cancer because it’s overexpressed 100- to 1000-fold higher compared to normal tissue\, is present during all stages of the disease\, and its transmembrane conformation enables internalization of the therapeutic. This case study presents a manufacturing process for DOTAGA-Labeled urea-based peptide PSMA inhibitor API\, DOTAGA-(I-y)fk(Sub-KuE). In only ten months\, process development and GMP manufacturing were accomplished on a multigram scale. Process and analytical method development were carried out concurrently in the first three months\, followed by a pilot batch (13g\, one month)\, a toxicology study batch (29g\, one month)\, and GMP production (45g\, two months). Optimization of the synthesis\, cleavage\, and purification steps ensures a high crude yield (85-90% purity) and an overall yield of > 65% (> 98% purity). Developing an effective\, validated HPLC method to remove chiral isomer impurities affords easy resolution and isolation of the final product.
URL:https://test.cpcscientific.com/event/prrt-case-study-presentation-at-the-2023-boulder-peptide-symposium/
LOCATION:Marriott Hotel & Spa\, Napa\, California\, 3425 Solano Ave\, Napa\, CA\, 94558\, United States
CATEGORIES:Exhibitions,Presentations
END:VEVENT
END:VCALENDAR